Focus: MapLight Therapeutics is a pre-revenue optogenetics-focused biotech company developing novel treatments for rare neuropsychiatric and neurodegenerative diseases. Operating at Series C+ stage from Burlington, MA, the company represents an early-stage, capital-intensive venture.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
MapLight is a high-risk, high-innovation-potential play suited for early-career scientists willing to sacrifice stability for platform ownership and optogenetics expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MapLight Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MapLight Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo